Evidence map›Paper›PMID 36947143›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India.

Seth A Hoffman, Christopher LeBoa, Kashmira Date, Pradeep Haldar, Pauline Harvey, Rahul Shimpi, Qian An, Chenhua Zhang, Niniya Jayaprasad, Lily Horng and 20 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Typhoid fever.Nature reviews. Disease primers · 2023
    Review
  14. Article
  15. Typhoid Fever: A Reduction and a Resurgence.The American journal of tropical medicine and hygiene · 2023
    Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 3 countries.

Seth A HoffmanDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-7881-3605
Christopher LeBoaDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Kashmira DateGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Pradeep HaldarMinistry of Health & Family Welfare, Government of India, New Delhi, India.
Pauline HarveyWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Rahul ShimpiWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Qian AnGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Chenhua ZhangGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Niniya JayaprasadWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Lily HorngDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Kirsten FagerliGlobal Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Priyanka BorhadeWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Savita DaruwallaDepartment of Pediatrics, NMMC General Hospital, Navi Mumbai, India.
Dhanya DharmapalanDr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India.
Jeetendra GavhaneDepartment of Pediatrics, MGM New Bombay Hospital, MGM Medical College, Navi Mumbai, India.
Shrikrishna JoshiDr. Joshi's Central Clinical Microbiology Laboratory, Navi Mumbai, India.
Rajesh RaiDepartment of Pediatrics & Neonatology, Dr. D.Y. Patil Medical College and Hospital, Navi Mumbai, India.
Varsha RathodRajmata Jijau Hospital, Airoli (NMMC), Navi Mumbai, India.
Keertana ShettyDepartment of Microbiology, Dr. D.Y. Patil Medical College and Hospital, Navi Mumbai, India.
Divyalatha S WarrierDepartment of Pediatrics, Mathadi Trust Hospital, Navi Mumbai, India.
Shalini YadavDepartment of Microbiology, MGM New Bombay Hospital, Navi Mumbai, India.
Debjit ChakrabortyNational Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India.
Sunil BahlWorld Health Organization South-East Asia Regional Office, New Delhi, India.
Arun KatkarWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Abhishek KunwarWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Vijay YewaleDr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India.
Jason R AndrewsDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Pankaj BhatnagarWorld Health Organization-Country Office for India, National Public Health Surveillance Project, New Delhi, India.
Shanta DuttaNational Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India.
Stephen P LubyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0001-5385-899X
World Health Organization - India · INStanford University · USCenters for Disease Control and Prevention · USAxis Multispecialty Hospital · INDr. D. Y. Patil Medical College, Hospital and Research Centre · INIndian Council of Medical Research · INBombay Hospital · INGovernment of India · INJoshi Hospital · INMahatma Gandhi Memorial Medical College · INWorld Health Organization Regional Office for South-East Asia · IN

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
EMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8M
FIC NIH HHS D43 TW010540NIAID NIH HHS T32 AI007502World Health Organization 001
6 · The paper itself

Abstract

backgroundThe World Health Organization recommends vaccines for prevention and control of typhoid fever, especially where antimicrobial-resistant typhoid circulates. In 2018, the Navi Mumbai Municipal Corporation (NMMC) implemented a typhoid conjugate vaccine (TCV) campaign. The campaign targeted all children aged 9 months through 14 years within NMMC boundaries (approximately 320 000 children) over 2 vaccination phases. The phase 1 campaign occurred from 14 July 2018 through 25 August 2018 (71% coverage, approximately 113 420 children). We evaluated the phase 1 campaign's programmatic effectiveness in reducing typhoid cases at the community level.

methodsWe established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai and offered blood cultures to children who presented with fever ≥3 days. We used a cluster-randomized (by administrative boundary) test-negative design to estimate the effectiveness of the vaccination campaign on pediatric typhoid cases. We matched test-positive, culture-confirmed typhoid cases with up to 3 test-negative, culture-negative controls by age and date of blood culture and assessed community vaccine campaign phase as an exposure using conditional logistic regression.

resultsBetween 1 September 2018 and 31 March 2021, we identified 81 typhoid cases and matched these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities (programmatic effectiveness, 56%; 95% confidence interval [CI], 25% to 74%; P = .002). Cases aged ≥5 years were 0.37 times as likely (95% CI, .19 to .70; P = .002) and cases during the first year of surveillance were 0.30 times as likely (95% CI, .14 to .64; P = .002) to live in vaccine campaign communities.

conclusionsOur findings support the use of TCV mass vaccination campaigns as effective population-based tools to combat typhoid fever.

Indexed as

Typhoid FeverTyphoid-Paratyphoid VaccinesAdolescentChildChild, PreschoolHumansIncidenceIndiaInfantProspective StudiesVaccines, AttenuatedVaccines, ConjugateTyphoid-Paratyphoid VaccinesVaccines, AttenuatedVaccines, Conjugateglobal healthIndiaSalmonella Typhityphoid fevervaccines

Identifiers

PMID36947143
PMCPMC10320126
OpenAlexW4353017168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.